|
KIAA1009 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62492241884138E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
4.97935026544383E-13 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
2.00361949254102E-12 |
| Stage1-vs-Stage2 |
1.811610E-01 |
| Stage1-vs-Stage3 |
5.894300E-02 |
| Stage1-vs-Stage4 |
5.585600E-02 |
| Stage2-vs-Stage3 |
9.398400E-01 |
| Stage2-vs-Stage4 |
6.255600E-01 |
| Stage3-vs-Stage4 |
6.420600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.11022302462516E-16 |
| Normal-vs-AfricanAmerican |
4.9146000002942E-07 |
| Normal-vs-Asian |
4.04719999735903E-08 |
| Caucasian-vs-AfricanAmerican |
7.346600E-01 |
| Caucasian-vs-Asian |
6.217900E-02 |
| AfricanAmerican-vs-Asian |
3.910400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.32587340685131E-15 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
6.838400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62581059726108E-12 |
| Normal-vs-Age(41-60Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(61-80Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(81-100Yrs) |
3.98780000000487E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.190400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.292000E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.894400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.826100E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.402600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.796400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.464700E-03 |
| Classical-VS-Follicular |
5.259400E-01 |
| Classical-VS-Other |
4.333400E-01 |
| Classical-VS-Normal |
8.04301070189695E-12 |
| Tall-VS-Follicular |
4.945600E-02 |
| Tall-VS-Other |
1.342780E-01 |
| Tall-VS-Normal |
1.78024261998644E-12 |
| Follicular-VS-Other |
2.402200E-01 |
| Follicular-VS-Normal |
1.16380238779357E-11 |
| Other-VS-Normal |
4.455500E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
2.23887575145909E-12 |
| N0-vs-N1 |
6.885000E-01 |
|
|
